BAY 11-7082

Catalog No.S2913 Synonyms: BAY 11-7821

BAY 11-7082 Chemical Structure

Molecular Weight(MW): 207.25

BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. Also inhibiting components of the ubiquitin system.

Size Price Stock Quantity  
In DMSO USD 120 In stock
USD 90 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 28 Publications

Purity & Quality Control

Choose Selective IκB/IKK Inhibitors

Biological Activity

Description BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. Also inhibiting components of the ubiquitin system.
Targets
E2-conjugating enzymes [6]
(Cell-free assay)
IκBα phosphorylation [1]
(Tumor cells)
10 μM
In vitro

BAY 11-7082 completely and specifically abrogates NF-κB DNA binding, downregulating the NF-κB-inducible cytokine IL-6 and inducing apoptosis. [1] BAY 11-7082 (< 8 μM) is able to effectively inhibit both basal and TNFα stimulated NFκB luciferase activity in a dose dependent manner. BAY 11-7082 (8 μM) strongly inhibits the rate of proliferation in NCI-H1703 cells. [2] Bay 11-7082 (5 μM) rapidly and efficiently reduces the DNA binding of NF-kappaB in HTLV-I-infected T-cell lines and down-regulates the expression of the antiapoptotic gene, Bcl-x(L), whereas it has little effect on the DNA binding of another transcription factor, AP-1. Bay 11-7082-induced apoptosis of primary ATL cells is more prominent than that of normal peripheral blood mononuclear cells, and apoptosis of these cells is also associated with down-regulation of NF-kappaB activity. Bay 11-7082 (5 μM) selectively induces apoptosis of HTLV-I–infected T-cell lines associated with down-regulation of the expression of cyclin D1, cyclin D2, and Bcl-xL. [3] BAY 11-7082 (100 μM) prevents the nuclear translocation of p65 elicited by NMDA and the NMDA-induced increase of NF-κB binding in mouse hippocampal slices. BAY 11-7082 prevents NMDA toxicity occurring in CA1 region of hippocampal slices with 40% neuroprotection at 20 μM and 70% neuroprotection at 100 μM. [4] BAY 11-7082 at all concentrations tested significantly inhibits NF-κB p65 DNA-binding activity in adipose tissue, whereas in skeletal muscle, BAY 11-7082 at 50 μM and 100 μM significantly inhibits NF-κB p65 DNA-binding activity. BAY 11-7082 (100 μM) reduces IKK-β protein in human adipose tissue and skeletal muscle. BAY 11-7082 (100 μM) significantly decreases the release of TNF-α from adipose tissue, whereas the release of IL-6 and IL-8 is significantly inhibited at all concentrations of BAY 11-7082 tested. BAY 11-7082 (50 μM) significantly decreases the release of TNF-α, IL-6, and IL-8 in skeletal muscle. [5] BAY 11-7082 is also found to inactivate the E2-conjugating enzymes Ubc (ubiquitin conjugating) 13 and UbcH7 and the E3 ligase LUBAC (linear ubiquitin assembly complex), and thus induces B-cell lymphoma and leukaemic T-cell death. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HeLa NEH1S3ZHfW6ldHnvckBCe3OjeR?= NHeyZ20yOMLizszN MWexMlUhcA>? MYDhZo9tcXOqZYOgRnBCKGmwZIXj[YQhfXBicnXneYxifGmxbjDv[kBHViCjbnSgUW1RNToEoB?= MWOyOVc6PzR|Nx?=
SiHa  NWLqcYtvTnWwY4Tpc44hSXO|YYm= NH3ORXEyOMLizszN MkPMNU42KGh? MoHqZYJwdGm|aHXzJGJRSSCrbnT1Z4VlKHWyIILl[5Vt[XSrb36gc4YhTk5iYX7kJG1OWC17wrC= MY[yOVc6PzR|Nx?=
ARPE-19 MUTGeY5kfGmxbjDBd5NigQ>? NIC3cIsyKM7:TR?= Ml:4NE42KGh? MWrzeZBxemW|c3XzJHRINWmwZIXj[YTDqEmOLUlCpJBzd22xdHXyJIFkfGm4YYTpc44> MXeyOVU6OzB{OR?=
HCT116 NH65VGFHfW6ldHnvckBCe3OjeR?= MkjUOUDPxE1? NYK5[VN[OiCq M4HPT2ROW09? NF7sNZBifHSnboXheIV{KHOrbIntZZJqdi2rbnT1Z4VlKGSxd37y[Yd2dGG2aX;uJI9nKGO7Y3zpckBFOQ>? MmOwNlU1Pzl5MkO=
HMECs MknUSpVv[3Srb36gRZN{[Xl? MojsOeKh|ryP MUiyJIg> M3W5OoFjd2yrc3jld{BVVkZvzsGtbY5lfWOnZDDWR2FONTFiZYjwdoV{e2mxbtMg MmHINlUyQTNzMU[=
A549  Mm[ySpVv[3Srb36gRZN{[Xl? M3rtNVEx6oDLwsXN MWWxNkBp NH7Fc2l{fXCycnXzd4V{KES4bD2zJIlv\HWlZXSgZYN1cX[jdHnvckBw\iCyNkW= M3PIe|I2OTV4OECw
RAW 264.7 MYnGeY5kfGmxbjDBd5NigQ>? M4qxVVXDqM7:TR?= M4f3dVEhcA>? MUHpcohq[mm2czDUUmYu|rFiYX7kJGlNNTF{IIC0NEBxem:mdXP0bY9v MYOyOVAyQTV4Nx?=
macrophages NXKySHNKTnWwY4Tpc44hSXO|YYm= MXu1JOK2VQ>? NFr6Npk{KGh? M{XWT5BienSrYXzsfUBjdG:la4OgXXBHWy2rbnT1Z4VlKGW6cILld5Nqd25ib3[gbW5QWyCjbnSgR29ZNTMEoB?= NUTDOWdVOjR7Nke4PVg>
HUVECs NITzO|lHfW6ldHnvckBCe3OjeR?= M2i3dFMuOzBizszN M3TjSFEhcA>? MoLudoVlfWOnczD0bIUh\XiycnXzd4lwdiCxZjDtbXIuOTR4YTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MY[yOFg3Ozl4NR?=
HeLa  M3vk[mZ2dmO2aX;uJGF{e2G7 NUTre3cxPcLizszN M3rpUFI1KGh? NUXXTYVqTE2VTx?= NFfoO5hz\WS3Y3XzJJRp\SCjY4Tpeol1gSCxZjDUUmYu|rFicILvcY91\XMEoB?= MX[yOFY2Pzd6Mx?=
A549 M2Lt[GZ2dmO2aX;uJGF{e2G7 MX6xNEDPxE1? MmH3NgKBkWh? NUnXNm9YcW6qaXLpeJMhfGinIHnuZ5Jm[XOnIH;mJJBpd3OyaH:tTe67Ss7zIHnuJHBCOTB|LXnu[oVkfGWmIHP1cJR2emW|wrC= NFz3RpUzPDZzMkS4PC=>
HUVEC NHjuSXFHfW6ldHnvckBCe3OjeR?= NWLSVZNvOjBiwsXN NGTLT24xNjViaB?= MkL2SG1UVw>? M2jpTZBz\X[nboTzJJRp\SCrbnT1Z5Rqd25ib3[gSWFOKGW6cILld5Nqd25? M1TXU|I1PTVzMkC5
A549RT-eto Mlm4RZBweHSxc3nzJGF{e2G7 MVuxNOKh|ryP NGXDdVMzPCCq MWDEUXNQ MXvhZ4NmdGW{YYTld{BHTVKRLX3l[IlifGWmIHHwc5B1d3Orcx?= M2jn[FI1PTN3MEiz
THP-1  MmfHSpVv[3Srb36gRZN{[Xl? M{C3d|AvOS9zwrFOwG0> MnLFNE42KGh? NIHRU3Ni[nKxZ3H0[ZMhXE6ILd8xJJNm[3KndHnvckBieyC5ZXzsJIF{KHSqZTDpcoNz\WG|ZXSgd4VkemW2aX;uJI9nKEmOLU[gZY5lKEmOLUJOti=> MUmyOFM4QDV|Nh?=
SKCXCR2  Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm3NkDDvU1? MUS0PEBp Mmjq[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvckB{cWewaX\pZ4FvfGy7 NUjTS3JYOjR|N{[3OFc>
SKCXCR2  NEOzR3VHfW6ldHnvckBCe3OjeR?= M3HIS|IhyrWP MWG0PEBp MmjWZoxw[2u|IITo[UBEYEOOMT3pcoR2[2WmIHPlcIwhcW64YYPpc44> MkfyNlQ{PzZ5NEe=
OVCXCR2 Mn3ySpVv[3Srb36gRZN{[Xl? NGPuT5EzKML3TR?= MmnROFghcA>? NWXRbI5o[myxY3vzJJRp\SCFWFPMNU1qdmS3Y3XkJINmdGxiaX72ZZNqd25? M1j5[VI1Ozd4N{S3
DSCs  NEnPSHlHfW6ldHnvckBCe3OjeR?= Mo\6Nk42KM7:TR?= MVGwMlUhcA>? M3j4XpJmfmW{c3XzJJRp\SCnbnjhcoNmdWWwdDDv[kBES0x{L1PDVlIh\XiycnXzd4lwdiCxZjDEV2N{KGmwZIXj[YQh[nliSVytN|M> MXSyOFM1PDJ2MB?=
WPs NUjiToM5TnWwY4Tpc44hSXO|YYm= MlfMNlUh|ryP M4fxTVUhdWmw MlO3d5VxeHKnc4Pld{BCXFBiYX7kJJZYTiC|ZXPy[ZRqd25? MWKyOFM{OTJyNx?=
A549RT-eto NX\mc5BGSXCxcITvd4l{KEG|c3H5 MmnUNVDDqM7:TR?= MoC5NlQhcA>? M2K5Z4Fk[2WuZYLheIV{KEZzNDDlfJRz[WO2LX3l[IlifGWmIHHwc5B1d3OrczDjc41jcW6nZDD0doVifG2nboSge4l1cCCIMUS= NXj6UGk3OjR{MkC3NlU>
A549RT-eto MXrGeY5kfGmxbjDBd5NigQ>? NX7wNGFWOTEEoN88US=> NXv6c2p5OjRiaB?= M3Xl[oRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdHNib3[gUmYu|rqEIHHu[EBRNWeywrC= MYWyOFIzODd{NR?=
FaDu MorBSpVv[3Srb36gRZN{[Xl? NX;NUWZbOiCq MVHpcohq[mm2czDwOlUh\XiycnXzd4lwdiCjbnSgZoxw[2u|IGTOSu6yNWmwZIXj[YQhXFeLU2Sg[ZhxemW|c3nvci=> MYKyOFIzODZ{Mh?=
IVD  NHHiPJpHfW6ldHnvckBCe3OjeR?= MoWxNVDDqM7:TR?= NY\IWllvOyCm NGTRS4Nz\X[ncoPld{BVVkZvzsJihLNu\WSrYYTl[EB{fXCycnXzd4lwdiCxZjD0bIUh\Gm|YzDtZZRzcXhibXHjdo9ud2ynY4Xs[ZMh[WepcnXjZY4h[W6mIHPvcIxi\2WwIFnJ NXq5VYllOjRzN{[4NFg>
IVD  NXzoVXZRTnWwY4Tpc44hSXO|YYm= MknJNVDDqM7:TR?= NGLKO5Y{KGR? M1fTTYFjem:pYYTld{BVVkZvzsJihLNqdmS3Y3XkJJVxNXKnZ4XsZZRqd25ib3[gRWRCVVSVLUSgZY5lKEGGQV3UV{02yqB? MnLnNlQyPzZ6MEi=
iNKT MVTGeY5kfGmxbjDBd5NigQ>? NFy4Uo8yOC9zMECg{txO NUjiNIxWOC53IHi= NGnRXWlqdmirYnn0d{B1cGViaX7keYN1cW:wIH;mJGEzSVJibWLORUBidmRib4To[ZIh\mGldH;y M2LGeVI1OTJ2NEWz
PC-3 NU\0dJl5TnWwY4Tpc44hSXO|YYm= MVeyMlUwPS9zMDFOwG0> M{PqUVAvPSCq NYDyTVFx[myxY3vzJGlITi2LST3pcoR2[2WmIGPUV{BuWk6DIHX4dJJme3Orb39CpC=> M1n1bFI1ODV3NUKw
THP-1  NUnZU3VbTnWwY4Tpc44hSXO|YYm= MUGxNOKh|ryP NWLrXVJVOcLiaB?= M4TRdYFjd2yrc3jld{B1cGViZX\m[YN1KG:oIILIV3AzPyCxbjDTVk1CKG2UTlG= MnL6NlM6Ozl|OUi=
A549 MXfGeY5kfGmxbjDBd5NigQ>? M{Hh[|HDqM7:TR?= M1iwUFQ5KGh? NHzpUFhmdmijbnPld{B1cGVidYCtdoVofWyjdHnvckBw\iCLzsrCJIFv\CC|dXLz[ZF2\W62IHTlZ5Jm[XOnIHnuJGJigCCneIDy[ZN{cW:wIHnu[JVk\WRiYomgZ49u[mmwZXSgd5RqdXWuYYTpc44> M1XweFI{QTByMEiw
A549 M2W3e2Fxd3C2b4Ppd{BCe3OjeR?= NUjXO5ZDOcLizszN MUm0PEBp NEPvWnRz\WS3Y3XzJJRp\SClZXzsJIRm[XSqIHnu[JVk\WRiYomgZ49u[mmwZXSgd5RqdXWuYYTpc44> NU\BSo14OjN7MECwPFA>
NCI-N87 NGTLbGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\vVJIyOC9{MD:zNEDPxE1? NEfuUVg3NzJ2IHi= MkLNd5VxeHKnc4Pld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 M3LWTFI{QDR4NUS1
AGS MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPzSmsyOC9{MD:zNEDPxE1? M{PaS|YwOjRiaB?= M3PGXJN2eHC{ZYPz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NV;sbVJ{OjN6NE[1OFU>
MGC80-3 NVXzOG86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq2[VRkOTBxMkCvN|Ah|ryP MnPzOk8zPCCq NX;we5V[e3WycILld5NmeyClZXzsJJZq[WKrbHn0fUB{cWewaX\pZ4FvfGy7 NVrXfHVNOjN6NE[1OFU>
HGC-27  MkPQSpVv[3Srb36gRZN{[Xl? MYO3MlUwOTVxM{Cg{txO MkTxOkBp NYLOR4ZjcW6mdXPld{B1cGViZHXwbI9{eGixconsZZRqd25iYX7kJJVxNXKnZ4XsZZRqd25ib3[gTe67Ss7z M4XKOVI{QDR4NUS1
MGC80-3 NGfUSZRHfW6ldHnvckBCe3OjeR?= Mk\1O{42NzF3L{OwJO69VQ>? MlzCOkBp MlTRbY5lfWOnczD0bIUh\GWyaH;zdIhwenmuYYTpc44h[W6mIIXwMZJm\3WuYYTpc44hd2ZiSd86Ru6y NUPZdpQxOjN6NE[1OFU>
HGC-27  MVHBdI9xfG:|aYOgRZN{[Xl? NUXsRZhvPy53L{G1M|MxKM7:TR?= NYfUTlE1PiCq MVXpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M2rtR|I{QDR4NUS1
HBE  NHzYVm9HfW6ldHnvckBCe3OjeR?= NHroXlEyOM7:TR?= MUezbC=> NF\MOlNi[m:uaYPo[ZMhfGinIHnuZ5Jm[XOnczDv[kBKVC14IHX4dJJme3Orb36gbY5lfWOnZDDifUBEW0V? MoHxNlM5OjRyOEm=
HepG2 MmfTSpVv[3Srb36gRZN{[Xl? Ml7pNE4{NzFxMzFOwG0> MVK0PEBp M4ezNpJm\HWlZYOgTWw3NWmwZIXj[YQhWE:QMTDlfJBz\XO|aX;u M2i4[lI{PzlzOEOz
THP-1 MYXGeY5kfGmxbjDBd5NigQ>? MmnhOUDDvU1? Ml7jNUBp NG\DZlhFVVOR MmnsbY5pcWKrdIOgUXRDNWmwZIXj[YQhVkcQulKgZYN1cX[jdHnvci=> M2jrc|I{PjN2MkG4
THP-1  MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTtR|JqPSEEtV2= MlrhOE85KGR? MUnEUXNQ MU\y[YR2[2W|IITo[UB3cWGkaXzpeJkhd2ZiaX70doFk\WyudXzhduKhVVSE MlK0NlM3OzR{MUi=
MDM MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4O5fFUhyrWP M1zqe|QwQCCm M3zjfGROW09? MVvy[YR2[2W|IITo[UB3cWGkaXzpeJkhd2ZiaX70doFk\WyudXzhduKhVVSE MYqyN|Y{PDJzOB?=
AM M{Tkemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrF[oE2KML3TR?= MUS0M|gh\A>? NWDDV3c1TE2VTx?= MVLy[YR2[2W|IITo[UB3cWGkaXzpeJkhd2ZiaX70doFk\WyudXzhduKhVVSE NUfkfpd1OjN4M{SyNVg>
RAW 264  MWrGeY5kfGmxbjDBd5NigQ>? Ml[3NE4zNTViwsXN MVmzNE83OC97MDDtbY4> M2Da[olvcGmkaYTzJJRp\SCyaH;zdIhifGG|ZTDhZ5Rqfmm2eTDv[kBRXFBzQtMg NHjMUJIzOzV5OEOwNi=>
HUVEC NXPsd|hUTnWwY4Tpc44hSXO|YYm= NWDINWlLOTEEoN88US=> Mn\mNE42KGh? NIGxXIRFVVOR NWfFSYpq[2:3boTldoFkfGW|IITo[UBtd3O|IH;mJHRq\TJibWLORS=> MoWxNlM2PjN4M{K=
HT29 NXHMPGViTnWwY4Tpc44hSXO|YYm= MoS1NVAwOzBxMUCwJO69VQ>? MknuNUBp NGHURVJqdmirYnn0[ZMh[m:2aDDUW2VCUy2rbnT1Z4VlKHBzMECgdJJw[2W|c3nu[y=> MXmyN|UzPzF3NB?=
HT29 M1nTO2Z2dmO2aX;uJGF{e2G7 NWnic3NwOTBxM{CvNVAxKM7:TR?= M4rSflEhcA>? NFXpeJJqdmirYnn0d{BVVkZvaX7keYNm\CCyaH;zdIhwenmuYYTpc44h[W6mIHTl[5Ji\GG2aX;uJI9nKEoQulNOtS=> NGLpZ|UzOzV{N{G1OC=>
MM.1S Mm\YRZBweHSxc3nzJGF{e2G7 NHHydlI{OCEEtV2= M4jXTVMhcA>? NYrjUoVTcW6mdXPld{BOVSClZXzsJIRm[XSqIHnueo9tfmW|IH7lZ5Jwe2m| MoqxNlM2OjdzNUS=
KMS-12-BM MmrlRZBweHSxc3nzJGF{e2G7 MkHsN|AhyrWP MXmzJIg> MUfpcoR2[2W|IF3NJINmdGxiZHXheIghcW64b3z2[ZMhdmWlcn;zbZM> MVqyN|UzPzF3NB?=
BAFs M2rjXmZ2dmO2aX;uJGF{e2G7 NHTXXGUxNjVxMdMg{txO M4XoW|I1KGh? MX\pcohq[mm2czDUUmbPuS:GRWigbY5lfWOnZDDDXXAyQUFzwrD0doFve2O{aYD0dy=> NYDUdXFCOjN2OEW0OVc>
SP6.5 MlT1SpVv[3Srb36gRZN{[Xl? Mor3OUDPxE1? NGnxb4IzKGh? M{\vNYRm[3KnYYPld:KhfHKjboPsc4NifGmxbjDv[kBxPjViaX6geIhmKG63Y3zleZPDqA>? NV[xb|VXOjN2NEOwPFY>
VUP NH34fo9HfW6ldHnvckBCe3OjeR?= MkPGOUDPxE1? MU[yJIg> NX[4XXFS\GWlcnXhd4V{yqC2cnHud4xw[2G2aX;uJI9nKHB4NTDpckB1cGViboXjcIV2e8Li NXW1T21LOjN2NEOwPFY>
OCM1 NFfhemtHfW6ldHnvckBCe3OjeR?= MmroOUDPxE1? MYGyJIg> NYXjRYNV\GWlcnXhd4V{yqC2cnHud4xw[2G2aX;uJI9nKHB4NTDpckB1cGViboXjcIV2e8Li MWSyN|Q1OzB6Nh?=
OM431 NVnlXJoyTnWwY4Tpc44hSXO|YYm= NFj6e5E2KM7:TR?= MX[yJIg> MoDm[IVkemWjc3XzxsB1emGwc3zvZ4F1cW:wIH;mJJA3PSCrbjD0bIUhdnWlbHX1d:Kh M2KxNlI{PDR|MEi2
SP6.5 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVuyMlUuOjBizszN Mo\jNlQhcMLi MmfRTWM2OD13IN88UUwh\XiqaXLpeJMhe3S{b37nJIFvfGlvcILvcIln\XKjdHn2[UBm\m[nY4TzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NEXkdGgzOzR2M{C4Oi=>
VUP MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTobYUzNjVvMkCg{txO MYGyOEBpyqB? M1LCSWlEPTB;NTFOwG0tKGW6aHnibZR{KHO2cn;u[{BidnSrLYDyc4xq\mW{YYTpeoUh\W[oZXP0d{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NYqzW2N1OjN2NEOwPFY>
OCM1 M1L4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHZdZZ7Oi53LUKwJO69VQ>? MojQNlQhcMLi M2jBe2lEPTB;NTFOwG0tKGW6aHnibZR{KHO2cn;u[{BidnSrLYDyc4xq\mW{YYTpeoUh\W[oZXP0d{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGWxT4QzOzR2M{C4Oi=>
OM431 NVTDOY5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTEcnp4Oi53LUKwJO69VQ>? M4K2dVI1KGkEoB?= MULJR|UxRTVizszNMEBmgGirYnn0d{B{fHKxbnegZY51cS2ycn;sbYZmemG2aY\lJIVn\mWldIOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGmyXZUzOzR2M{C4Oi=>
SP6.5 NFLq[ZVCeG:ydH;zbZMhSXO|YYm= MoLwOUDPxE1? M2PoTVI1KGkEoB?= MX;pcoR2[2W|IHHwc5B1d3Orc9Mg M1;mRVI{PDR|MEi2
VUP MYDBdI9xfG:|aYOgRZN{[Xl? MmHBOUDPxE1? MXeyOEBpyqB? MVjpcoR2[2W|IHHwc5B1d3Orc9Mg NIDhOJkzOzR2M{C4Oi=>
OCM1 M1vhbWFxd3C2b4Ppd{BCe3OjeR?= NWnwVG5rPSEQvF2= MV[yOEBpyqB? M2HYUIlv\HWlZYOgZZBweHSxc3nzxsA> MYKyN|Q1OzB6Nh?=
OM431 M1i3S2Fxd3C2b4Ppd{BCe3OjeR?= NY\HWY86PSEQvF2= M1LEU|I1KGkEoB?= NUP2WGxHcW6mdXPld{BieG:ydH;zbZPDqA>? NYrC[W9rOjN2NEOwPFY>
SP6.5 MkjDSpVv[3Srb36gRZN{[Xl? NFzz[no2KM7:TR?= M4Kzd|EzKGh? M4PEN5Jm\HWlZYOgeIhmKG2rZ4LheIlwdsLi NEK5RVAzOzR2M{C4Oi=>
VUP M{jJRWZ2dmO2aX;uJGF{e2G7 MYS1JO69VQ>? MlzzNVIhcA>? MV\y[YR2[2W|IITo[UBucWe{YYTpc47DqA>? MkXVNlM1PDNyOE[=
OCM1 NUHZU2VuTnWwY4Tpc44hSXO|YYm= NETRVo82KM7:TR?= NEjQNYMyOiCq NYrncY9uemWmdXPld{B1cGVibXnndoF1cW:wwrC= NGTCUogzOzR2M{C4Oi=>
OM431 MX3GeY5kfGmxbjDBd5NigQ>? NE\xWIk2KM7:TR?= M1HIeFEzKGh? MnzHdoVlfWOnczD0bIUhdWmpcnH0bY9vyqB? MVSyN|Q1OzB6Nh?=
HBL-1  M2jFXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYKzxsDPxE1? M{S1TlI1NzR6L{eyJIg> M4nGTWROW09? NFG5eVB{dG:5czDj[YxtKGe{b4f0bEBud2Snc4TsfS=> M4\QNFI{PDRzN{Ow
RAW 264.7 M1:xZ2Z2dmO2aX;uJGF{e2G7 NVnkZm1TOi1zNTFOwG0> M3nxflEhcA>? MWnEUXNQ NGToXld{fXCycnXzd4V{KHSqZTDhZ5RqfmG2aX;uJI9nKEmNSzDmZY1qdHlibXXtZoVzew>? NGW0c5YzOzR2MUezNC=>
IL-1R  M3nlRWZ2dmO2aX;uJGF{e2G7 NYXPc5lMOi1zNTFOwG0> MkPrNUBp MWHEUXNQ M3vhNZN2eHC{ZYPz[ZMhfGinIHHjeIl3[XSrb36gc4YhUUuNIH\hcYltgSCvZX3i[ZJ{ NEK3[ZQzOzR2MUezNC=>
RAW 264.7 NX\KXodUTnWwY4Tpc44hSXO|YYm= NF73NFcyPSEQvF2= M13VVVEhcA>? MVHEUXNQ MmTmd5VxeHKnc4Pld{B1cGViYXP0bZZifGmxbjDv[kBidmRiSl7L Mk\ONlM1PDF5M{C=
IL-1R  M4nXe2Z2dmO2aX;uJGF{e2G7 M4TiNFE2KM7:TR?= Mkf3NUBp MYTEUXNQ NXLKTnd7e3WycILld5NmeyC2aHWgZYN1cX[jdHnvckBw\iCjbnSgTm5M MWCyN|Q1OTd|MB?=
U2OS M3P2fGZ2dmO2aX;uJGF{e2G7 NGrrRlEyPSEQvF2= NGDtUJQyKGh? MVnEUXNQ NUiwSYtGeHKndnXueJMhfGinIFzQV{0hd3JiSVytNU1{fGmvdXzheIVlKG[xcn3heIlwdiCxZjDLOlMueFWkIHPoZYlve8Li NUnlZ2NXOjN2NEG3N|A>
MT‐1  MUPGeY5kfGmxbjDBd5NigQ>? MXS4xsDDvW1? NUTEV|Y4OyCq NXHPOZJT\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdQKBmFOWQWSzJIFv\CCy4pEQOGVDWDF? NHjzTI8zOzJ5OES3PS=>
MT‐2  NFfXWHFHfW6ldHnvckBCe3OjeR?= NHL1d|I5yqEEtX2= MVWzJIg> MoL5[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicPMAlHNVSVR|IHHu[EBx6oDSNFXCVFE> MoTVNlMzPzh2N{m=
MT‐1  MnzMSpVv[3Srb36gRZN{[Xl? MnG5POKhyrWv M1X4cVMhcA>? NVm1VmV[\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKHB4NTDzeYJ2dmm2IH;mJG5H6oDSzsrCxsA> NVrTUm1vOjN{N{i0O|k>
MT‐2  NV\DXHFHTnWwY4Tpc44hSXO|YYm= M2DnNVjDqML3bR?= MVWzJIg> M1zmU4Rm[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBxPjVic4XieY5qfCCxZjDOSwKBmM78QtMg MlOwNlMzPzh2N{m=
MCF-7  NWrIWVFyTnWwY4Tpc44hSXO|YYm= NWC4N3V6Oi53LUG1JO69VQ>? NWfK[FhVOC53IHi= MYXEUXNQ NWjpRm5N[2G3c3XzJJRp\SCpcnHkeYFtKGyxc4Ogc4Yh[2WubDDh[Ihme2mxbh?= Mk\yNlMxQTN{Mke=
HaCaT  NUnCW3kzTnWwY4Tpc44hSXO|YYm= MX[1MlDDqM7:TR?= MUOxxsBpyqB? NGrLSnZifHSnboXheIV{KHSqZTDUR29JNWmwZIXj[YQheHKxZIXjeIlwdiCxZjDJUE03yqB? NEftSmszOzB2MUG2PC=>
A549  NYPLfnI{TnWwY4Tpc44hSXO|YYm= NHjOVlYyKGh? M1L0cIlvcGmkaYTzJGxVSS2rbnT1Z4VlKFOSLVGgcXJPSSCycn;keYN1cW:wwrDzbYdvcW[rY3HueIx6 NUnV[3JMOjNyM{GyNVM>
OA chondrocytes  M2e4[2Z2dmO2aX;uJGF{e2G7 MXuxNEDPxE1? NIrFSJEyKGh? MkTjZoxw[2u|IITo[UBCT0VvQmPBMYlv\HWlZXSg[4Vv\S:ycn;0[YlvKGW6cILld5Nqd25ib3[gS3JRPzhib4KgR29ZNTJiKIC8NE4xPSl? NIHvZ2czOjl6MkKyPC=>
RAW264.7 NGjWPWxHfW6ldHnvckBCe3OjeR?= MU[xOUDPxE1? MlvXNVUuOTJyIH3pci=> NI\ObItjdG:la4OgeIhmKHC{b3T1Z5Rqd25ib3[gUm8tKFCJRUKsJIFv\CCWTl[t{tE> NGS0S3EzOjd2NUWyNy=>
RAW264.7 NVPpUXpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXqwfpFZPS1|MDFOwG0> M{\qU|I1KGh? NVe2TVVxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mlz6NlI4PDV3MkO=
HBL6 MnjhRZBweHSxc3nzJGF{e2G7 NVfzRphEOC53L{WvNlUh|ryP M33zUlYwOjRiaB?= M1KzVYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDhcoQhdGWnYXTzJJRwKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5mesLi MXOyNlA4PDh{MB?=
HT29  NFT2OoRHfW6ldHnvckBCe3OjeR?= NUG3[25nOS1zMDFOwG0> M4HqOVExyqCq NYDhTFlYcW6lcnXhd4V{KEiRLUGgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u M1PC[VIyPjJyOU[0
Ca9–22 M3P2PWFxd3C2b4Ppd{BCe3OjeR?= MnfZNVDDqM7:TdMg NVnScmk{OSCq NH\jfmJkd22ybHX0[Yx6KGmwaHnibZR{KEGOQT3QSHQucW6mdXPl[EBieG:ydH;zbZM> MnSxNlEyOzh2OEC=
Ca9–22 MoDuSpVv[3Srb36gRZN{[Xl? MWixNOKh|ryPwrC= MXKxJIg> M3OyToNwdXCuZYTlcJkh[WK{b3fheIV{KHSqZTDBUGEuWESWLXnu[JVk\WRiSl7LJIFkfGm4YYTpc44> MU[yNVE{QDR6MB?=
A-549 M1nyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX5c5VvOTEEoN88UeKh NFrXSW8zPC92ODDo M3;Y[YlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgeIlu\S2mZYDlcoRmdnRibXHucoVz M2DHO|IxQDZ4MESz
AP NYOweZRLTnWwY4Tpc44hSXO|YYm= M2XaV|UwOTBizszN M1:0elQ5KGh? M{fJZ4Rwf26{ZXf1cIF1\XNidHjlJGJCTCCycn;0[YlvKGyndnXsJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MoTENlA2QTZ4NEW=
AQ1 MoXnSpVv[3Srb36gRZN{[Xl? MkjZOU8yOCEQvF2= MVG0PEBp NHv6cm1ld3ewcnXneYxifGW|IITo[UBDSURicILveIVqdiCuZY\lcEBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWXzeHBGOjB3OU[2OFU>
AP NVzTW|dbTnWwY4Tpc44hSXO|YYm= MnLzNlAh|ryP MVm0M|ghcA>? MVHkc5dvemWpdXzheIV{KHSqZTDCRWQheHKxdHXpckBt\X[nbDDhJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MlTDNlA2QTZ4NEW=
AQ1 NWfvcVVMTnWwY4Tpc44hSXO|YYm= MorENlAh|ryP M17WflQwQCCq NX36TZRl\G:5boLl[5Vt[XSnczD0bIUhSkGGIIDyc5RmcW5ibHX2[Ywh[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NWO4WWpwOjB3OU[2OFU>
THP-1 MYnGeY5kfGmxbjDBd5NigQ>? MlvlOeKh|ryPwrC= NYq3epdJOC53IHi= NInhPWxifHSnboXheIV{KHSqZTDMVHMucW6mdXPl[EBxNUoQulNOtUBxem:2ZXnuJIJ6KDd{JR?= Mm\hNlA{ODl5MUi=
K562 NGfuZ|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjnemw5Oi1|MDFOwG0> MXSyOEBp MlewTWM2OD16IN88UUxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NX3w[G1MOTl4NE[4NFc>
Jurket MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVj1fVRQOi1|MDFOwG0> MoHkNlQhcA>? MnPyTWM2OD15LkGg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWXTWopqOTl4NE[4NFc>
U937 M4e1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVOyMVMxKM7:TR?= M2PselI1KGh? NUjVZlQxUUN3ME2xNE42KM7:TTygbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFu5fGMyQTZ2NkiwOy=>
PBMC MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU[yMVMxKM7:TR?= NV7IR2p7OjRiaB?= M4XNPGlEPTB;NECuNkDPxE1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MnPtNVk3PDZ6MEe=
K562 M1zaNmFxd3C2b4Ppd{BCe3OjeR?= MoLDNk0zOMLizszNxsA> MkLYNlQhcA>? NV;2WmJbcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JIFxd3C2b4Ppdy=> M2PQcFE6PjR4OEC3

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:[2]
+ Expand
  • Cell lines: NCI-H1703 cells
  • Concentrations: ~8 μM
  • Incubation Time: 12 hours
  • Method: Cells are transfected with siRNA in 96-well microtiter plates and then cultured for 72 hours in complete NSCLC medium, treated with BAY 11-7082 for 12 hours. Cells are incubated with [3H]thymidine for 3 hours. The cells are collected on filters using an automatic cell harvester and radioactivity on the filters is measured by β-scintillation counting.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 41 mg/mL (197.82 mM)
Ethanol 10 mg/mL (48.25 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 207.25
Formula

C10H9NO2S

CAS No. 19542-67-7
Storage powder
in solvent
Synonyms BAY 11-7821

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IκB/IKK Signaling Pathway Map

IκB/IKK Inhibitors with Unique Features

Related IκB/IKK Products4

Tags: buy BAY 11-7082 | BAY 11-7082 supplier | purchase BAY 11-7082 | BAY 11-7082 cost | BAY 11-7082 manufacturer | order BAY 11-7082 | BAY 11-7082 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID